AU2001273983A1 - Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy - Google Patents

Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy

Info

Publication number
AU2001273983A1
AU2001273983A1 AU2001273983A AU7398301A AU2001273983A1 AU 2001273983 A1 AU2001273983 A1 AU 2001273983A1 AU 2001273983 A AU2001273983 A AU 2001273983A AU 7398301 A AU7398301 A AU 7398301A AU 2001273983 A1 AU2001273983 A1 AU 2001273983A1
Authority
AU
Australia
Prior art keywords
hydroxy
dihydro
indoles
benzo
prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273983A
Inventor
Anja Fecher
Tobias Herzig
Lutz F. Tietze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000121335 external-priority patent/DE10021335A1/en
Priority claimed from DE10025329A external-priority patent/DE10025329A1/en
Application filed by Individual filed Critical Individual
Publication of AU2001273983A1 publication Critical patent/AU2001273983A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Abstract

The chemotherapy of malignant tumours is greatly restricted by the generally slight differentiation of the available cytostatic agents between normal and malignant tissue. In order to achieve an improvement of the selectivity in cancer therapy, novel prodrugs have been developed from 6-hydroxy-2,3-dihydro-1H-indolene, 5-hydroxy-1,2-dihydro-3H-pyrrolo[3,2-e]indolene and 5-hydroxy-1,2-dihydro-3H-benzo[e]indolene as well as from 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]-quinolines, that may be used within the framework of the ADEP therapy (antibody directed enzyme prodrug therapy). The new prodrugs are characterised by a high difference in toxicity between the prodrug and underlying drug and by a very high efficacy of the drug. After splitting off of the glycosidic and/or acetal group on the phenolic hydroxy groups of the prodrugs, a spirocyclopropacyclohexadiene is formed which, being a highly toxic group, effects an alkylation of the DNA or RNA.
AU2001273983A 2000-05-02 2001-05-02 Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy Abandoned AU2001273983A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE2000121335 DE10021335A1 (en) 2000-05-02 2000-05-02 New 6-hydroxy-2,3-dihydro-1H-indole derivatives, tricyclic analogs and corresponding glycoside prodrugs, are antitumor agents for use in antibody-directed enzymatic prodrug therapy
DE10021335 2000-05-02
DE10025329A DE10025329A1 (en) 2000-05-23 2000-05-23 New 6-hydroxy-2,3-dihydro-1H-indole derivatives and analogs, useful in cancer therapy, especially used in low toxicity glycoside or acetal prodrug form for antibody directed enzyme prodrug therapy
DE10025329 2000-05-23
PCT/EP2001/004904 WO2001083448A2 (en) 2000-05-02 2001-05-02 Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]quinoline derivatives for use in selective cancer therapy

Publications (1)

Publication Number Publication Date
AU2001273983A1 true AU2001273983A1 (en) 2001-11-12

Family

ID=26005518

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273983A Abandoned AU2001273983A1 (en) 2000-05-02 2001-05-02 Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy

Country Status (6)

Country Link
US (1) US7214685B2 (en)
EP (1) EP1280771B1 (en)
AT (1) ATE279390T1 (en)
AU (1) AU2001273983A1 (en)
DE (1) DE50104114D1 (en)
WO (1) WO2001083448A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2004035571A1 (en) * 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20050239864A1 (en) * 2004-04-23 2005-10-27 Yuqiang Wang Novel tumor-selective chemotherapeutic agents
RU2489423C2 (en) * 2006-02-02 2013-08-10 Синтарга Б.В. Water-soluble analogues cc-1065 and their conjugates
MX2009007987A (en) 2007-01-25 2010-03-01 Dana Farber Cancer Inst Inc Use of anti-egfr antibodies in treatment of egfr mutant mediated disease.
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
EP2173739B1 (en) * 2007-08-01 2013-07-31 Syntarga B.V. Substituted cc-1065 analogs and their conjugates
JP5532486B2 (en) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Monoclonal antibody 175 targeting EGF receptor and derivatives and uses thereof
US8144909B2 (en) 2008-08-12 2012-03-27 Cochlear Limited Customization of bone conduction hearing devices
MX2011004625A (en) 2008-11-03 2011-07-20 Syntarga Bv Novel cc-1065 analogs and their conjugates.
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
DE102009051438A1 (en) 2009-10-30 2011-05-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts fluorescent dyes
DE102009051799B4 (en) 2009-11-03 2021-07-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bifunctional Prodrugs and Drugs
PL2560645T3 (en) 2010-04-21 2017-01-31 Syntarga B.V. Conjugates of cc-1065 analogs and bifunctional linkers
CN101857617A (en) * 2010-04-28 2010-10-13 中国海洋大学 Quinazoline sugar derivative and preparation method and application thereof
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
CN103503484B (en) 2011-03-23 2017-07-21 耳蜗有限公司 The allotment of hearing device
SI2820009T1 (en) 2012-03-01 2018-05-31 Array Biopharma, Inc. Serine/threonine kinase inhibitors
MY177390A (en) 2014-01-10 2020-09-14 Byondis Bv Method for purifying cys-linked antibody-drug conjugates
MX368234B (en) 2014-01-10 2019-09-25 Synthon Biopharmaceuticals Bv Duocarmycin adcs for use in treatment of endometrial cancer.
SG10201911860VA (en) 2014-01-10 2020-02-27 Synthon Biopharmaceuticals Bv Duocarmycin adcs showing improved in vivo antitumor activity
ES2785551T3 (en) 2014-06-30 2020-10-07 Glykos Finland Oy Saccharide derivative of a toxic payload and its conjugates with antibodies
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646298A (en) 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
US5843937A (en) 1996-05-23 1998-12-01 Panorama Research, Inc. DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents
JP4155598B2 (en) 1996-09-12 2008-09-24 オークランド ユニサーヴィシズ リミテッド Condensed N-acylindoles as anticancer agents

Also Published As

Publication number Publication date
US7214685B2 (en) 2007-05-08
EP1280771A2 (en) 2003-02-05
EP1280771B1 (en) 2004-10-13
WO2001083448A3 (en) 2002-06-20
DE50104114D1 (en) 2004-11-18
US20040033962A1 (en) 2004-02-19
ATE279390T1 (en) 2004-10-15
WO2001083448A2 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
AU2001273983A1 (en) Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy
AU2959595A (en) Camptothecin drug combinations and medicaments with reduced side effects
AU3835285A (en) Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
HRP950337A2 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
BR0014320A (en) Compositions of therapeutic substances soluble in tocol
ATE200677T1 (en) SUBSTITUTED TETRA- AND PENTAPETIDE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
AR023616A1 (en) COMBINED PREPARATIONS UNDERSTANDING ANTHRACICLINE DERIVATIVES
AU2795000A (en) Epothilone derivatives and their use as antitumor agents
EP1423107A4 (en) Fatty alcohol drug conjugates
EP1017675A4 (en) Highly lipophilic camptothecin derivatives
AU2001292579A1 (en) Methods and compounds for treating proliferative diseases
IL138079A0 (en) 5-aminoindeno (1,2-c) pyrazol-4-ones as anti-cancer and anti-proliferative agents
NO20021859L (en) New oligosaccharides, their preparation and pharmaceutical preparations containing the oligosaccharides
PL342614A1 (en) Anticarcinogenic drugs
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2002010152A3 (en) Novel indole derivatives and their use as medicaments
Aguero et al. Phenoxodiol inhibits growth of metastatic prostate cancer cells
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
AU5705099A (en) Compounds useful as aicarft inhibitors
MXPA03003798A (en) Tricyclic derivatives of indole with antiangiogenic activity.
Abe et al. Prevention of growth of human lung carcinoma cells and induction of apoptosis by a novel phenoxazinone, 2-amino-4, 4α-dihydro-4α, 7-dimethyl-3H-phenoxazine-3-one
Sánchez‐del‐Campo et al. Targeting the methionine cycle for melanoma therapy with 3‐O‐(3, 4, 5‐trimethoxybenzoyl)‐(−)‐epicatechin
WO2022061155A9 (en) Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7